{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:50:16Z","timestamp":1791841816390,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,12,22]],"date-time":"2009-12-22T00:00:00Z","timestamp":1261440000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurosci Behav Physi"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s11055-009-9244-1","type":"journal-article","created":{"date-parts":[[2009,12,21]],"date-time":"2009-12-21T06:17:03Z","timestamp":1261376223000},"page":"149-155","source":"Crossref","is-referenced-by-count":41,"title":["Use of Memantine (akatinol) for the Correction of Cognitive Impairments in Parkinson\u2019s Disease Complicated by Dementia"],"prefix":"10.1007","volume":"40","author":[{"given":"I. V.","family":"Litvinenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Odinak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. I.","family":"Mogil\u2019naya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. V.","family":"Perstnev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,12,22]]},"reference":[{"key":"9244_CR1","unstructured":"D. V. Artem\u2019ev and Zh. M. Glozman, \u201cImpairments to higher mental functions in Parkinson\u2019s disease,\u201d in : Advances in Neurodegeneration [in Russian], Moscow (1995), pp. 46\u201360."},{"issue":"2","key":"9244_CR2","first-page":"78","volume":"5","author":"SI Gavrilova","year":"1995","unstructured":"S. I. Gavrilova, Ya. B. Kalyn, I. V. Kolykhalov, et al., \u201cAkatinol memantine \u2013 a modulator of the glutamatergic system in the treatment of Alzheimer\u2019s-type dementia,\u201d Sots. Klin. Psikhiat., 5, No. 2, 78\u201389 (1995).","journal-title":"Sots. Klin. Psikhiat."},{"issue":"10","key":"9244_CR3","first-page":"15","volume":"105","author":"OS Levin","year":"2005","unstructured":"O. S. Levin, \u201cEfficacy of reminil in Lewy body dementia,\u201d Zh. Nevropatol. Psikhiat., 105, No. 10, 15\u201321 (2005).","journal-title":"Zh. Nevropatol. Psikhiat."},{"key":"9244_CR4","first-page":"76","volume":"4","author":"IV Litvinenko","year":"2004","unstructured":"I. V. Litvinenko and M. M. Odinak, \u201cPathogenetic bases of the formation of cognitive and psychotic impairments in Parkinson\u2019s disease,\u201d Zh. Nevrol. Psikhiat., 4, 76\u201381 (2004).","journal-title":"Zh. Nevrol. Psikhiat."},{"key":"9244_CR5","volume-title":"Parkinson\u2019s Disease","author":"IV Litvinenko","year":"2006","unstructured":"I. V. Litvinenko, Parkinson\u2019s Disease [in Russian], Miklosh, Moscow (2006), p. 216."},{"issue":"1","key":"9244_CR6","first-page":"26","volume":"107","author":"MN Puzin","year":"2007","unstructured":"M. N. Puzin, O. V. Krivonos, and Zh. V. Kozhevnikova, \u201cAkatinol memantine in the treatment of cognitive impairments in Parkinson\u2019s disease,\u201d Zh. Nevrol. Psikhiat., 107, No. 1, 26\u201329 (2007).","journal-title":"Zh. Nevrol. Psikhiat."},{"key":"9244_CR7","unstructured":"N. N. Yakhno, T. V. Akhutina, and V. V. Zakharov, \u201cMemory impairments in Parkinson\u2019s disease,\u201d in: Proc. of the 7th All-Russian Congr. of Neurologists [in Russian], N. Novgorod (1995), p. 573."},{"issue":"6","key":"9244_CR8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1212\/WNL.56.6.730","volume":"56","author":"D Aarsland","year":"2001","unstructured":"D. Aarsland, K. Andresen, J. P. Larsen, et al., \u201cRisk of dementia in Parkinson\u2019s Disease: A community-based prospective study,\u201d Neurology, 56, No. 6, 730\u2013736 (2001).","journal-title":"Neurology"},{"issue":"10","key":"9244_CR9","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/gps.949","volume":"18","author":"D Aarsland","year":"2003","unstructured":"D. Aarsland, M. Hutchinson, and J. P. Larsen, \u201cCognitive, psychiatric and motor response to galantamine in Parkinson\u2019s disease with dementia,\u201d Int. J. Geriat. Psychiat., 18, No. 10, 937\u2013941 (2003).","journal-title":"Int. J. Geriat. Psychiat."},{"key":"9244_CR10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.2005.083113","volume":"78","author":"D Aarsland","year":"2007","unstructured":"D. Aarsland, K. Br\u00f8nnick, U. Ehrt, et al., \u201cNeuropsychiatric symptoms in patients with Parkinson\u2019s disease and dementia: frequency, profile and associated care giver stress,\u201d J. Neurol. Neurosurg. Psychiatr., 78, 36\u201342 (2007).","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"9244_CR11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev.ne.09.030186.002041","volume":"9","author":"GE Alexander","year":"1986","unstructured":"G. E. Alexander, M. R. DeLong, and P. L. Strick, \u201cParallel organization of functionally segregated circuits linking basal ganglia and cortex,\u201d Ann. Rev. Neurosci., 9, 357\u2013381 (1986).","journal-title":"Ann. Rev. Neurosci."},{"issue":"1","key":"9244_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neurobiolaging.2006.09.002","volume":"29","author":"I Blasko","year":"2008","unstructured":"I. Blasko, K. Jellinger, G. Kemmler, et al., \u201cConversion from cognitive health to mild cognitive impairment and Alzheimer\u2019s disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine,\u201d Neurobiol. Aging, 29, No. 1, 1\u201311 (2008).","journal-title":"Neurobiol. Aging"},{"issue":"3","key":"9244_CR13","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1017\/S0033291700029901","volume":"21","author":"JL Boyd","year":"1991","unstructured":"J. L. Boyd, C. A. Cruickshank, C. W. Kenn, et al., \u201cCognitive impairment and dementia in Parkinson\u2019s disease: a controlled study,\u201d Psychological. Med., 21, No. 3, 911\u2013921 (1991).","journal-title":"Psychological. Med."},{"issue":"13","key":"9244_CR14","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1212\/01.wnl.0000306632.43729.24","volume":"70","author":"TC Buter","year":"2008","unstructured":"T. C. Buter, A. Van den Hout, F. E. Matthews, et al., \u201cDementia and survival in Parkinson disease: a 12-year population study,\u201d Neurology, 70, No. 13, 1017\u20131022 (2008).","journal-title":"Neurology"},{"issue":"3","key":"9244_CR15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.neulet.2005.10.027","volume":"394","author":"AS Caumont","year":"2006","unstructured":"A. S. Caumont, J. N. Octave, and E. Hermans, \u201cAmantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells,\u201d Neurosci. Lett., 394, No. 3, 196\u2013201 (2006).","journal-title":"Neurosci. Lett."},{"issue":"12","key":"9244_CR16","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","volume":"44","author":"JL Cummings","year":"1994","unstructured":"J. L. Cummings, M. Mega, K. Gray, et al., \u201cThe Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia,\u201d Neurology, 44, No. 12, 2308\u20132314 (1994).","journal-title":"Neurology"},{"key":"9244_CR17","doi-asserted-by":"crossref","unstructured":"N. Egashira, R. Okuno, S. Harada, et al., \u201cEffects of glutamate-related drugs on marble-burying behavior in mice: Implications for obsessive-compulsive disorder,\u201d Eur. J. Pharmacol. (E-publication ahead of print) (2008).","DOI":"10.1016\/j.ejphar.2008.01.035"},{"issue":"4","key":"9244_CR18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1474-4422(03)00351-X","volume":"2","author":"M Emre","year":"2003","unstructured":"M. Emre, \u201cDementia associated with Parkinson\u2019s disease,\u201d Lancet Neurol., 2, No. 4, 229\u2013237 (2003).","journal-title":"Lancet Neurol."},{"key":"9244_CR19","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","volume":"351","author":"M Emre","year":"2004","unstructured":"M. Emre, D. Aarsland, A. Albanese, et al., \u201cRivastigmine for dementia associated with Parkinson\u2019s disease,\u201d New Eng. J. Med., 351, 2509\u20132518 (2004).","journal-title":"New Eng. J. Med."},{"issue":"1","key":"9244_CR20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s100720200022","volume":"23","author":"G Fabbrini","year":"2002","unstructured":"G. Fabbrini, P. Barbanti, C. Aurilia, et al., \u201cDonepezil in the treatment of hallucinations and delusions in Parkinson\u2019s disease,\u201d Neurol. Sci., 23, No. 1, 41\u201343 (2002).","journal-title":"Neurol. Sci."},{"issue":"2","key":"9244_CR21","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1124\/jpet.107.122036","volume":"322","author":"M Giustizieri","year":"2007","unstructured":"M. Giustizieri, M. L. Cucchiaroni, R. Guatteo, et al., \u201cMemantine inhibits ATP-dependent K+ conductances in dopamine neurons of the rat substantia nigra pars compacta,\u201d J. Pharmacol. Exp. Ther., 322, No. 2, 721\u2013729 (2007).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"9244_CR22","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/mds.20968","volume":"21","author":"R Inzelberg","year":"2006","unstructured":"R. Inzelberg, U. Bonuccelli, E. Schechtman, et al., \u201cAssociation between amantadine and the onset of dementia in Parkinson\u2019s disease,\u201d Mov. Dis., 21, No. 9, 1375\u20131379 (2006).","journal-title":"Mov. Dis."},{"issue":"18","key":"9244_CR23","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1097\/WNR.0b013e3282f29100","volume":"18","author":"Y Luo","year":"2007","unstructured":"Y. Luo, X. Zhou, X. Yang, and J. Wang, \u201cHomocysteine induces tau hyperphosphorylation in rats,\u201d Neuroreport, 18, No. 18, 2005\u20132008 (2007).","journal-title":"Neuroreport"},{"key":"9244_CR24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mds.870090112","volume":"9","author":"J Martinez-Martin","year":"1994","unstructured":"J. Martinez-Martin, A. Cil-Nagel, L. Morlan-Garcia, et al., \u201cUnified Parkinson\u2019s Disease Rating Scale: characteristics and structure,\u201d Mov. Dis., 9, 76\u201383 (1994).","journal-title":"Mov. Dis."},{"issue":"5","key":"9244_CR25","first-page":"273","volume":"22","author":"M Merello","year":"1999","unstructured":"M. Merello, M. I. Nouzeilles, A. Cammarota, and R. Leiguarda, \u201cEffect of memantine (NMDA antagonist) on Parkinson\u2019s disease: a double-blind crossover randomized study,\u201d Clin. Neuropharmacol., 22, No. 5, 273\u2013276 (1999).","journal-title":"Clin. Neuropharmacol."},{"issue":"3","key":"9244_CR26","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0028-3908(99)00019-2","volume":"38","author":"CG Parsons","year":"1999","unstructured":"C. G. Parsons, W. Danysz, and G. Quack, \u201cMemantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist \u2013 a review of preclinical data,\u201d Neuropharmacology, 38, No. 3, 735\u2013767 (1999).","journal-title":"Neuropharmacology"},{"issue":"6","key":"9244_CR27","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.pnpbp.2006.04.013","volume":"30","author":"M Pasquini","year":"2006","unstructured":"M. Pasquini and M. Biondi, \u201cMemantine augmentation for refractory obsessive-compulsive disorder,\u201d Prog. Neuropsychopharmacol. Biol. Psychiat., 30, No. 6, 1173\u20131175 (2006).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiat."},{"issue":"11","key":"9244_CR28","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1176\/appi.ajp.162.11.2191-a","volume":"162","author":"M Poyurovsky","year":"2005","unstructured":"M. Poyurovsky, R. Weizman, A. Weizman, and L. Koran, \u201cMemantine for treatment-resistant OCD,\u201d Am. J. Psychiat., 162, No. 11, 2191\u20132192 (2005).","journal-title":"Am. J. Psychiat."},{"issue":"1\u20132","key":"9244_CR29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neulet.2006.05.040","volume":"404","author":"D Religa","year":"2006","unstructured":"D. Religa, K. Czyzewski, M. Styczynska, et al., \u201cHyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson\u2019s disease,\u201d Neurosci. Lett., 404, No. 1\u20132, 56\u201360 (2006).","journal-title":"Neurosci. Lett."},{"issue":"Supplement 1","key":"9244_CR30","first-page":"20","volume":"127","author":"M Rosler","year":"2002","unstructured":"M. Rosler, \u201cThe efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia,\u201d Int. J. Clin. Pract., 127, Supplement 1, 20\u201326 (2002).","journal-title":"Int. J. Clin. Pract."},{"issue":"2","key":"9244_CR31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/syn.20472","volume":"62","author":"P Seeman","year":"2008","unstructured":"P. Seeman, C. Caruso, M. Lasaga, \u201cMemantine agonist action at dopamine D2High receptors,\u201d Synapse, 62, No. 2, 149\u2013153 (2008).","journal-title":"Synapse"},{"issue":"2","key":"9244_CR32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1212\/01.WNL.0000129986.19019.5D","volume":"63","author":"CB Wright","year":"2004","unstructured":"C. B. Wright, H. S. Lee, M. C. Paik, et al., \u201cTotal homocysteine and cognition in a tri-ethnic cohort: the Northern Manhattan Study,\u201d Neurology, 63, No. 2, 254\u2013260 (2004).","journal-title":"Neurology"}],"container-title":["Neuroscience and Behavioral Physiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11055-009-9244-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11055-009-9244-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11055-009-9244-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T04:04:58Z","timestamp":1559361898000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11055-009-9244-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,22]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["9244"],"URL":"https:\/\/doi.org\/10.1007\/s11055-009-9244-1","relation":{},"ISSN":["0097-0549","1573-899X"],"issn-type":[{"value":"0097-0549","type":"print"},{"value":"1573-899X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,22]]}}}